Investors sweet on Nektar as phase 2b eczema success doubles share price

Nektar Therapeutics' stock soared 119% following positive Phase 2b clinical trial results for its atopic dermatitis drug, rezpegaldesleukin (rezpeg), which met its primary endpoint with a 61% symptom improvement on the high dose. Despite the data trailing market leader Dupixent, Nektar emphasizes rezpeg's differentiated mechanism as an IL-pathway agonist and rapid onset of response, positioning the company for a Phase 3 trial. This success marks a significant turnaround for Nektar, re-evaluating its prospects after prior clinical setbacks.

Analysis

Nektar Therapeutics (NKTR) has reported a significant clinical success with positive top-line data from its Phase 2b trial of rezpegaldesleukin in atopic dermatitis, triggering a 119% premarket stock increase to $20.90. The trial successfully met its primary endpoint, with the high dose demonstrating a 61% symptom improvement versus 31% for placebo over 16 weeks. Key secondary endpoints also showed statistical significance, with up to 46% of patients on rezpeg achieving a 75% improvement on the EASI score (EASI-75) and 25% achieving EASI-90. While a clear win against placebo, these efficacy figures trail the established market leader, Dupixent from Regeneron and Sanofi, which posted EASI-75 and EASI-90 scores of 52% and 30%, respectively, in its own trials. Management is positioning rezpeg based on its differentiated mechanism as an IL-pathway agonist that stimulates regulatory T-cells to rebalance the immune system, rather than blocking it. The company also highlights a rapid onset of response as a key differentiator against other emerging therapies like OX40 inhibitors. This positive readout marks a critical turning point for Nektar, which previously suffered major setbacks including a collapsed oncology partnership with Bristol Myers Squibb and the termination of a collaboration with Eli Lilly on this same asset, restoring confidence after a period where the company's valuation traded below its cash holdings. Nektar now has a clear path forward and intends to advance to a Phase 3 trial with high confidence in the trial design.

Key Decisions for Investors

• Investors should re-evaluate Nektar as a de-risked clinical-stage biotech, but recognize that future valuation gains are dependent on successful Phase 3 execution and demonstrating commercial differentiation in a crowded market.
• The primary risk to consider is rezpeg's competitive positioning against Dupixent, as the Phase 2 efficacy data, while positive, suggests it may not displace the market leader but could carve out a niche for a subset of patients.
• Monitor future disclosures on the Phase 3 trial design, specifically the chosen dose, as the Phase 2 data indicated the middle dose performed numerically better than the high dose on the key EASI-75 metric.
• For those holding Regeneron or Sanofi, this result introduces a new potential competitor, but its current data profile does not pose an immediate threat to Dupixent's dominant market share.